Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 2400Neoplasms 1819Carcinoma, Non-Small-Cell Lung 1599Prostatic Neoplasms 1298Colorectal Neoplasms 1140Lung Neoplasms 984Neoplasm Metastasis 830Multiple Myeloma 792Leukemia, Myeloid, Acute 767Ovarian Neoplasms 674Pancreatic Neoplasms 662Melanoma 660Squamous Cell Carcinoma of Head and Neck 586Carcinoma, Hepatocellular 567Recurrence 562Brain Neoplasms 527Glioblastoma 513Head and Neck Neoplasms 500Stomach Neoplasms 497Triple Negative Breast Neoplasms 465Lymphoma 454Uterine Cervical Neoplasms 450Carcinoma, Renal Cell 425Precursor Cell Lymphoblastic Leukemia-Lymphoma 410Lymphoma, Non-Hodgkin 389Endometrial Neoplasms 381Sarcoma 368Lymphoma, Follicular 356Urinary Bladder Neoplasms 354Hematologic Neoplasms 352

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Muscle-Invasive Bladder Carcinoma × 1 year × Clear all
NCT05295992 2026-03-06

ARTIA-Vesica

Varian, a Siemens Healthineers Company

Phase NA Active not recruiting
110 enrolled

Muscle-Invasive Bladder Carcinoma

NCT04506554 2025-07-04

A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer

Fox Chase Cancer Center

Phase 2 Active not recruiting
81 enrolled

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡